Clinical Trial Update: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) [Phase 3]

View source ↗

Summary

The document reports the completion of an extension to a long-term safety study of ALKS 9072 (ALKS 9070) in schizophrenia, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ALKS 9072 (ALKS 9070)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2017-08-25